Microbot Medical Inc. (MBOT)
After hours:
| Previous close | 0.9899 |
| Open | 1.0300 |
| Bid | 1.0200 x 400 |
| Ask | 1.0500 x 400 |
| Day's range | 1.0100 - 1.0400 |
| 52-week range | 0.8600 - 2.4700 |
| Volume | |
| Avg. volume | 2,769,270 |
| Market cap | 16.604M |
| Beta (5Y monthly) | 1.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8600 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireMicrobot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trialBRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Cen
ZacksMicrobot Medical (MBOT) Progresses in Its Human Clinical Trial
Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.
- GlobeNewswire
Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular Robotic Surgical System. BRAINTREE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute,
